‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

Author: The Guardian

Date: 6/17/25

Language: English

Learn More: https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead

You might also enjoy

Sweden’s new antibiotic factory could serve as EU and NATO strategic asset

Open drug pricing activist MSF signs secrecy pacts with Big Pharma

FINALLY, THE PANDEMIC AGREEMENT!!! …… Many missed opportunities, but a beginning made

Findings from T1International’s 2024 Out-of-Pocket Expenses and Rationing Survey

Free trade agreement with Malaysia: Switzerland imperils the rights to food and health

Making Access to Quality Healthcare a Top Priority for the EU